Ting Sun1, Yabin Wang1, Xinjiang Wang2, Wenchao Hu1, Ang Li1, Sulei Li1, Xian Xu2, Ruihua Cao1, Li Fan3, Feng Cao4. 1. Chinese PLA Medical College & Department of Cardiology, National Clinic Research Center Geriatric Disease, 2nd Medical Center of Chinese PLA General Hospital, Beijing, 100853, China. 2. Department of Radiology, 2nd Medical Center of Chinese PLA General Hospital, Beijing, 100853, China. 3. Chinese PLA Medical College & Department of Cardiology, National Clinic Research Center Geriatric Disease, 2nd Medical Center of Chinese PLA General Hospital, Beijing, 100853, China. fl6698@163.com. 4. Chinese PLA Medical College & Department of Cardiology, National Clinic Research Center Geriatric Disease, 2nd Medical Center of Chinese PLA General Hospital, Beijing, 100853, China. fengcao8828@163.com.
Abstract
OBJECTIVES: To investigate the long-term effects of intensive LDL cholesterol-lowering treatments on lumen stenosis severity, plaque calcification, spotty calcifications, percent calcified plaque volume (PCPV), and Agatston coronary artery calcium score (CACS) based on coronary computed tomography angiography (CCTA) in elderly patients. METHODS: A total of 240 patients over 60 years old (comprising 754 lesions) who underwent serial CCTA were retrospectively enrolled in this 5-year cohort study. Patients were divided into three groups: an intensive lipid-lowering group, a lipid-lowering group, and a control group. The stenosis severity, plaque volume (PV), plaque composition, PCPV, and high-risk plaque (HRP) presence were quantitatively analyzed. The CACS was calculated at baseline and follow-up. RESULTS: All patients were male with an average age of 66.8 ± 5.8 years old. Over time, increases in the percentages of obstructive coronary lesions (p < 0.001) were observed. Compared with those at baseline, the percentage of obstructive lesions remained unchanged (p = 0.077), and the percentage of spotty calcifications significantly decreased (p < 0.05) at the follow-up CCTA scan in the intensive lipid-lowering group. Patients in the intensive lipid-lowering group demonstrated a higher progression in calcified PV, CACS, and PCPV (all p < 0.05), and a significantly greater attenuation in fibrous-fatty and lipid-rich PV (all p < 0.05) than patients in other groups. CONCLUSIONS: The PV and contents increased gradually with time in all groups. Intensive LDL-C lowering was associated with slower progression of stenosis severity and reduction of high-risk plaque features, with increased plaque calcification and higher progression in PCPV. Comprehensive serial plaque evaluations by CCTAs may contribute to further refinement of risk stratification and reasonable lipid-lowering treatment in elderly patients. KEY POINTS: • Intensive LDL-C lowering increased coronary calcification and percent calcified plaque volume progression. • Comprehensive serial plaque evaluations by serial CCTAs may help to refine risk stratification.
OBJECTIVES: To investigate the long-term effects of intensive LDL cholesterol-lowering treatments on lumen stenosis severity, plaque calcification, spotty calcifications, percent calcified plaque volume (PCPV), and Agatston coronary artery calcium score (CACS) based on coronary computed tomography angiography (CCTA) in elderly patients. METHODS: A total of 240 patients over 60 years old (comprising 754 lesions) who underwent serial CCTA were retrospectively enrolled in this 5-year cohort study. Patients were divided into three groups: an intensive lipid-lowering group, a lipid-lowering group, and a control group. The stenosis severity, plaque volume (PV), plaque composition, PCPV, and high-risk plaque (HRP) presence were quantitatively analyzed. The CACS was calculated at baseline and follow-up. RESULTS: All patients were male with an average age of 66.8 ± 5.8 years old. Over time, increases in the percentages of obstructive coronary lesions (p < 0.001) were observed. Compared with those at baseline, the percentage of obstructive lesions remained unchanged (p = 0.077), and the percentage of spotty calcifications significantly decreased (p < 0.05) at the follow-up CCTA scan in the intensive lipid-lowering group. Patients in the intensive lipid-lowering group demonstrated a higher progression in calcified PV, CACS, and PCPV (all p < 0.05), and a significantly greater attenuation in fibrous-fatty and lipid-rich PV (all p < 0.05) than patients in other groups. CONCLUSIONS: The PV and contents increased gradually with time in all groups. Intensive LDL-C lowering was associated with slower progression of stenosis severity and reduction of high-risk plaque features, with increased plaque calcification and higher progression in PCPV. Comprehensive serial plaque evaluations by CCTAs may contribute to further refinement of risk stratification and reasonable lipid-lowering treatment in elderly patients. KEY POINTS: • Intensive LDL-C lowering increased coronary calcification and percent calcified plaque volume progression. • Comprehensive serial plaque evaluations by serial CCTAs may help to refine risk stratification.
Authors: Sidney C Smith; Rod Jackson; Thomas A Pearson; Valentin Fuster; Salim Yusuf; Ole Faergeman; David A Wood; Michael Alderman; John Horgan; Philip Home; Marilyn Hunn; Scott M Grundy Journal: Circulation Date: 2004-06-29 Impact factor: 29.690
Authors: Rishi Puri; Stephen J Nicholls; Mingyuan Shao; Yu Kataoka; Kiyoko Uno; Samir R Kapadia; E Murat Tuzcu; Steven E Nissen Journal: J Am Coll Cardiol Date: 2015-04-07 Impact factor: 24.094
Authors: Sang-Eun Lee; Hyuk-Jae Chang; Ji Min Sung; Hyung-Bok Park; Ran Heo; Asim Rizvi; Fay Y Lin; Amit Kumar; Martin Hadamitzky; Yong Jin Kim; Edoardo Conte; Daniele Andreini; Gianluca Pontone; Matthew J Budoff; Ilan Gottlieb; Byoung Kwon Lee; Eun Ju Chun; Filippo Cademartiri; Erica Maffei; Hugo Marques; Jonathon A Leipsic; Sanghoon Shin; Jung Hyun Choi; Kavitha Chinnaiyan; Gilbert Raff; Renu Virmani; Habib Samady; Peter H Stone; Daniel S Berman; Jagat Narula; Leslee J Shaw; Jeroen J Bax; James K Min Journal: JACC Cardiovasc Imaging Date: 2018-06-13
Authors: Steven E Nissen; Stephen J Nicholls; Ilke Sipahi; Peter Libby; Joel S Raichlen; Christie M Ballantyne; Jean Davignon; Raimund Erbel; Jean Charles Fruchart; Jean-Claude Tardif; Paul Schoenhagen; Tim Crowe; Valerie Cain; Kathy Wolski; Marlene Goormastic; E Murat Tuzcu Journal: JAMA Date: 2006-03-13 Impact factor: 56.272
Authors: D H Blankenhorn; S P Azen; D M Kramsch; W J Mack; L Cashin-Hemphill; H N Hodis; L W DeBoer; P R Mahrer; M J Masteller; L I Vailas; P Alaupovic; L J Hirsch Journal: Ann Intern Med Date: 1993-11-15 Impact factor: 25.391
Authors: Robert Detrano; Alan D Guerci; J Jeffrey Carr; Diane E Bild; Gregory Burke; Aaron R Folsom; Kiang Liu; Steven Shea; Moyses Szklo; David A Bluemke; Daniel H O'Leary; Russell Tracy; Karol Watson; Nathan D Wong; Richard A Kronmal Journal: N Engl J Med Date: 2008-03-27 Impact factor: 91.245
Authors: Steven E Nissen; E Murat Tuzcu; Paul Schoenhagen; B Greg Brown; Peter Ganz; Robert A Vogel; Tim Crowe; Gail Howard; Christopher J Cooper; Bruce Brodie; Cindy L Grines; Anthony N DeMaria Journal: JAMA Date: 2004-03-03 Impact factor: 56.272
Authors: Hui Gu; Yang Gao; Zhihui Hou; U Joseph Schoepf; Alan N Snyder; Taylor M Duguay; Ximing Wang; Bin Lu Journal: Eur Radiol Date: 2017-09-29 Impact factor: 5.315